Skip to Content


Class: Platelet-aggregation Inhibitors
- Antithrombotic Agents
- Platelet-aggregation Inhibitors
- GPIIb/IIIa Receptor Inhibitors
ATC Class: B01AC17
Chemical Name: N-(butylsulfonyl)-4-[4-(4-piperidyl)butoxy]-l-phenylalanine monohydrochloride monohydrate
Molecular Formula: C22H36N2O5S
CAS Number: 144494-65-5
Brands: Aggrastat

Medically reviewed by Last updated on Sep 9, 2019.


Platelet-aggregation inhibitor;1 15 22 a platelet glycoprotein (GP IIb/IIIa)-receptor inhibitor.b

Uses for Tirofiban

Non-ST-Segment-Elevation Acute Coronary Syndromes

Adjunct to anticoagulant therapy (e.g., heparin [referring throughout this monograph to unfractionated heparin], low molecular weight heparin), aspirin, and a P2Y12-receptor antagonist (e.g., clopidogrel, prasugrel, ticagrelor) to reduce risk of acute cardiac ischemic events (death and/or MI) in patients with non-ST-segment-elevation acute coronary syndromes (NSTE ACS) (i.e., unstable angina or non-ST-segment-elevation MI [NSTEMI]), including those who are to receive medical management or to undergo PCI.1 5 6 21 91 994 995 1100

Adjunctive therapy with a GP IIb/IIIa-receptor inhibitor can reduce the incidence of cardiac ischemic events, including subsequent MI and death, in patients with NSTE ACS.5 6 11 35 36 42 46 51 71 72 73 80 83 84 85 91

The American College of Cardiology Foundation (ACCF) and AHA recommend either clopidogrel or IV administration of a GP IIb/IIIa-receptor inhibitor in addition to aspirin therapy prior to diagnostic angiography (“upstream”) in patients in whom an initial invasive management strategy is planned; eptifibatide or tirofiban is the preferred GP IIb/IIIa-receptor inhibitor for this use.991

The American College of Chest Physicians (ACCP) states that a clear risk-benefit profile has not been established for the use of GP IIb/IIIa-receptor inhibitors in patients with ACS who are not routinely scheduled for early revascularization.1016

In patients undergoing PCI, ACCF, AHA, and the Society for Cardiovascular Angiography and Intervention (SCAI) state that administration of a GP IIb/IIIa-receptor inhibitor at the time of PCI may be used as an adjunct to heparin in those with high-risk features (e.g., elevated troponin) who are not receiving bivalirudin and are not adequately pretreated with clopidogrel.994

Regarding choice of GP IIb/IIIa-receptor inhibitor in patients undergoing PCI, IV abciximab, “double-bolus” IV eptifibatide, and high-dose tirofiban by direct IV injection all produce a high degree of platelet inhibition and reduce ischemic complications.994

Tirofiban and eptifibatide not recommended by AHA in women with NSTE ACS who are at lower risk for adverse events and are managed with a conservative strategy, because of little demonstrated benefit and possible detrimental effects.109

ACCF, AHA, SCAI, and other experts currently do not recommend routine use of GP IIb/IIIa-receptor inhibitors in patients with ST-segment-elevation MI (STEMI) undergoing PCI; however, selective use of these drugs as an adjunct to heparin may be reasonable in certain high-risk patients (e.g., those with large anterior MI and/or large thrombus).994 1016

Tirofiban Dosage and Administration


  • Administer as soon as possible following diagnosis.21 91

  • Discontinue at least 4–6 hours prior to CABG.21 91

Adjunctive Antithrombotic Therapy

  • In clinical trials, almost all patients receiving tirofiban also received concomitant aspirin and/or heparin.1 5 6 11 14 Tirofiban and heparin may be administered through the same IV line.1

  • Aspirin: In clinical studies, patients received 300–325 mg daily for at least 48 hours after randomization or within 12 hours prior to PCI, unless the drug was contraindicated; some patients received aspirin indefinitely.1 5 6 11 14 ACCF/AHA/SCAI recommends aspirin 325 mg prior to PCI in patients not already receiving maintenance aspirin therapy.994 Patients already receiving maintenance aspirin therapy should receive 81–325 mg before the procedure.994

  • P2Y12-receptor antagonist: A loading dose of clopidogrel, prasugrel, or ticagrelor also is recommended in patients undergoing PCI with stent placement.994 995

  • Heparin during medical management: In clinical studies, patients received an IV loading dose of 5000 units followed by continuous IV infusion of 1000 units/hour.1 5 6 (See Laboratory Monitoring under Cautions.)

  • Heparin prior to PCI: In clinical studies, patients undergoing PCI after at least 48 hours of medical management received an IV loading dose of 5000–7500 units followed by continuous IV infusion of 1000 units/hour titrated to an aPTT approximately 2 times the control value with additional IV injections of heparin as needed.1 6 (See Laboratory Monitoring under Cautions.)

  • Heparin prior to urgent PCI: In a clinical study, patients at high risk for abrupt closure of the affected coronary artery who underwent urgent or emergency PCI received an IV loading dose of 10,000 units (body weight ≥70 kg) or 150 units/kg (body weight <70 kg).1 11 37 44 Additional injections during PCI were administered to maintain target activated clotting time (ACT) between 300–400 seconds.1 11 37 44

  • The manufacturer and other experts suggest use of lower dosages of concomitant IV heparin (50–70 units/kg) prior to PCI and targeted to an ACT of ≥200 seconds.1 18 35 44 53 71 74 77 80 81 95 96 (See Laboratory Monitoring under Cautions.)

  • Postprocedural use of heparin not recommended.6 11 42 52 53


IV Administration

For solution and drug compatibility information, see Compatibility under Stability.

Administer by IV infusion using either diluted injection concentrate or premixed injection in plastic (IntraVia™) containers.1 1

Discard unused portion.1

The plastic container of the premixed injection may be somewhat opaque because of moisture absorption during sterilization; this opacity will diminish gradually.1

Do not introduce additives into the injection container.1

Do not use the plastic IV container in series connections with other plastic containers; such use may result in air embolism.1


Tirofiban hydrochloride injection concentrate for IV infusion must be diluted to 50 mcg/mL (the same concentration as the premixed injection) before administration.1

Prepare injection concentrate for infusion by withdrawing and discarding 50 or 100 mL of solution from a 250- or 500-mL bag, respectively, of 0.9% sodium chloride or 5% dextrose injection and replacing this volume with an equivalent volume (i.e., 50 or 100 mL, respectively) of tirofiban hydrochloride injection to achieve a final concentration of 50 mcg/mL.1 21

Alternatively, a vial labeled as containing 5 mg of tirofiban may be added to a 100 mL bag of 0.9% sodium chloride injection or 5% dextrose injection.1

Mix solutions well prior to infusion.1

Rate of Administration

Administer as a continuous infusion.1 20 21 91


Available as tirofiban hydrochloride; dosage expressed in terms of tirofiban.1



Patients receiving medical therapy: IV loading dose of 0.4 mcg/kg per minute for 30 minutes given as soon as possible after diagnosis, followed by continuous IV infusion of 0.1 mcg/kg per minute for at least 24–48 hours.21 91

Patients who undergo PCI: IV loading dose of 0.4 mcg/kg per minute for 30 minutes followed by continuous IV infusion of 0.1 mcg/kg per minute given during angiography and for 12–24 hours after angioplasty or atherectomy.1 20 21 91

Special Populations

Hepatic Impairment

No specific dosage recommendations at this time.1 20

Renal Impairment

In patients with severe renal impairment (i.e., Clcr ≤30 mL/minute), decrease the usual loading and maintenance rate of infusion by 50%.1

Geriatric Patients

Dosage adjustment not required.1

Cautions for Tirofiban


  • Active internal bleeding or history of bleeding diathesis 1 5 6 14 20 21 91 within previous 30 days.1 20 21 91

  • History of intracranial hemorrhage, intracranial neoplasm, arteriovenous malformation, or aneurysm.1 52

  • History of thrombocytopenia following prior exposure to tirofiban.1 5 6 11 20 52

  • History of stroke within 30 days or any history of hemorrhagic stroke.1 5 6 11 14 20 52

  • Recent (within 30 days) major surgery or severe physical trauma.1 5 20 52

  • History, symptoms, or findings suggestive of aortic dissection.1 20

  • Severe uncontrolled hypertension (SBP >180 or DBP >110 mm Hg).1 5 20

  • Concomitant therapy with another parenteral GP IIb/IIIa-receptor inhibitor.1 20

  • Acute pericarditis.1 20

  • Known hypersensitivity to tirofiban or any ingredient in the formulation.1 20



Hematologic Effects

Risk of major bleeding (e.g., intracranial hemorrhage, GU or GI bleeding, bleeding at arterial access site) and minor bleeding (e.g., spontaneous gross hematuria, spontaneous hematemesis); may require blood or platelet transfusions.1 5 6 11 20 21 91 (See Bleeding Precautions and also see Laboratory Monitoring under Cautions.)

Pulmonary alveolar hemorrhage, spinal-epidural hematoma, retroperitoneal bleeding, and hemopericardium reported rarely.1

Fatal hemorrhage reported rarely.1

Use with caution in patients with platelet count <150,000/mm3, anemia (hemoglobin <10–12 g/dL), hemorrhagic retinopathy, and those requiring chronic hemodialysis.1 20 91

Use with caution in patients receiving other drugs that affect hemostasis (e.g., thrombolytic agents, oral anticoagulants, NSAIAs, dipyridamole, ticlopidine, and clopidogrel).1 20 21 91 (See Specific Drugs under Interactions.)

If bleeding cannot be controlled by pressure, discontinue tirofiban and concomitant heparin.1 20

Sensitivity Reactions

Hypersensitivity Reactions

Anaphylaxis and other severe allergic reactions reported on the first day of infusion, during initial treatment, and during readministration of the drug.1 21

Severe allergic reactions sometimes associated with severe thrombocytopenia (platelet counts <10,000/mm3).1

General Precautions

Bleeding Precautions

To reduce risk of bleeding, adhere to strict anticoagulation guidelines; use a short course of low-dose, weight-adjusted heparin; avoid vascular and other trauma; carefully manage vascular (e.g., femoral artery) access site; and monitor all potential bleeding sites during and following treatment.1 5 6 11 21 91

In patients undergoing PCI, use caution in the placement, maintenance, and removal of vascular access sheath; avoid femoral vein sheath placement.1 18 35 37 42 46 52 When inserting sheath, puncture only anterior wall of femoral artery; avoid Seldinger (through and through) technique.1 18 20 52 77 81 Observe appropriate precautions while sheath is in place (e.g., complete bed rest, elevation of head ≤30°, restrain limb in which sheath is inserted, frequent monitoring of vascular access site and distal pulse in the involved limb).1 18 19 20 52 Following PCI, consider early sheath removal (during tirofiban IV infusion).1 Prior to removal of sheath, discontinue heparin for 3–4 hours and allow aPTT to return to <45 seconds or ACT to <180 seconds.1 11 14 20 30 41 52 53 70 Discontinue tirofiban and heparin and achieve hemostasis (by applying pressure to femoral artery for at least 20–30 minutes after sheath removal18 19 ) at least 4 hours before hospital discharge.1 20 Measure and monitor hematomas for enlargement.18

To avoid vascular and other trauma, minimize needle punctures (e.g., arterial, IM, IV, lumbar, sub-Q, intradermal), cutdown sites, and use of nasotracheal intubation, nasogastric tubes, urinary catheters,1 18 20 and automatic BP cuffs18 during and following treatment;1 18 avoid establishment of IV access at noncompressible sites (e.g., subclavian or jugular veins);1 18 consider using an indwelling venipuncture device (e.g., heparin lock) for drawing blood; document and monitor vascular puncture sites; and remove dressings gently and carefully.18


Thrombocytopenia reported.1 5 32 37 43 44 45 50 52 Severe thrombocytopenia (platelet count <20,000/mm3) reported less frequently than with abciximab.18 30 32 35 37 44 50 53

Determine platelet counts prior to treatment and periodically (e.g., within the first 6 hours of the loading infusion, and daily thereafter) during concomitant tirofiban and heparin therapy.1 11 20 43 44 Consider possibility of pseudothrombocytopenia or heparin-induced thrombocytopenia in patients receiving concomitant heparin therapy.1 20 35 37 52 (See Thrombocytopenia under Cautions.)

If true thrombocytopenia is verified, discontinue tirofiban and initiate appropriate treatment and monitoring.1 Thrombocytopenia usually reversible following discontinuance of GP IIb/IIIa-receptor inhibitors and anticoagulant (heparin) therapy; consider platelet transfusions for the management of severe thrombocytopenia.35 37 43 52

Use with caution in patients with platelet count <150,000/mm3;1 20 contraindicated in patients with a history of thrombocytopenia following prior exposure to tirofiban.1 5 6 11 20 52

Laboratory Monitoring

Prior to administration, within the first 6 hours of the loading infusion and at least daily thereafter, obtain hematocrit and hemoglobin,1 11 20 35 43 44 and platelet counts.1 11 20 35 43 44

Closely monitor ACT or aPTT.1 30 52 70 Monitor aPTT 6 hours after the start of the heparin infusion and maintain at 50–70 seconds or approximately 2 times the control value unless PCI is to be performed.1 6 30 In patients undergoing PCI, measure the ACT.21 52 70 In patients undergoing PCI in clinical studies, ACT was maintained between 300–400 seconds during PCI;1 11 37 44 ACCP suggests targeting ACT between 200–250 seconds to reduce risk of major bleeding.1 18 35 44 53 71 74 77 80 81 95 96 Monitor aPTT or ACT prior to arterial sheath removal; do not remove sheath unless aPTT <45 seconds or ACT <180 seconds.1 30 41 53 70

Determine platelet counts prior to administration, within the first 6 hours of the loading infusion and at least daily thereafter.1 11 20 43 44 Perform additional platelet counts if a patient experiences a reduction in platelet count to <90,000/mm3 to exclude the possibility of pseudothrombocytopenia.1 18 90

Specific Populations


Category B.1


Distributed into milk in rats;1 not known whether distributed into human milk.1 Discontinue nursing or the drug.1

Pediatric Use

Safety and efficacy not established.1 20

Geriatric Use

No substantial differences in efficacy relative to younger adults.1 However, increased incidence of bleeding complications and non-bleeding adverse events in some studies.1 20


Increased incidence of minor bleeding complications and non-bleeding adverse events in some studies.1 109

Hepatic Impairment

Clearance not affected in patients with mild to moderate hepatic impairment;1 20 information on plasma clearance limited in patients with severe hepatic impairment since these patients were excluded from participation in clinical studies.21

Renal Impairment

Substantially decreased clearance (>50%) in patients with severe renal impairment (i.e., Clcr ≤30 mL/minute), including patients requiring hemodialysis;1 reduced dosage recommended in such patients.1 20 (See Renal Impairment under Dosage and Administration.)

Use with caution in patients requiring chronic hemodialysis.1 20 91

Common Adverse Effects

Bleeding,1 pelvic pain,1 coronary artery dissection,1 bradycardia,1 leg pain,1 dizziness,1 edema/swelling, 1 vasovagal reaction,1 sweating.1

Interactions for Tirofiban

Specific Drugs




Anticoagulants, oral

Potential increased risk of bleeding1

Use with caution1 20 21 91


Potential increased risk of bleeding1 4 22

Use with caution1 20 21 91


Increased risk of bleeding1

Some clinicians recommend against concomitant use91


Potential increased risk of bleeding1

Use with caution1 20 21 91

GP IIb/IIIa-receptor inhibitors (abciximab, eptifibatide)

Possible additive pharmacologic effects1 4

Concomitant use contraindicated1


Increased risk of bleeding; 1 5 6 11 14 possible additive effects on ACT56

Monitor aPTT or ACT during therapy;1 5 6 11 37 44 consider dosage adjustment of heparin56


Possible increased tirofiban clearance 1

Clinical importance not known1


Potential increased risk of bleeding1

Use with caution1 20 21 91


Possible increased tirofiban clearance 1

Clinical importance not known1


Increased risk of bleeding1

Use concomitantly with caution; no concomitant use studies to date20 21 91


Potential increased risk of bleeding1 4 22

Use with caution1 20 21 91

Tirofiban Pharmacokinetics



Rapid onset;11 14 20 90% inhibition of platelet aggregation occurs by the end of the IV loading infusion administration.1 20 21


Short duration of action;11 14 20 platelet aggregation persists during maintenance infusion.1 20 21 Platelet function generally recovers within 4–8 hours following discontinuance of infusion.1 20



Distributed into milk in rats and crosses the placenta in pregnant rats and rabbits.1 20 Not known whether tirofiban crosses the placenta or is distributed into milk in humans.1 20

Plasma Protein Binding

Approximately 65%.1 4 20



Metabolism appears limited.1 20

Elimination Route

Excreted in urine (65%) and in feces (25%) mainly as unchanged drug.1 20


Approximately 1.2–2 hours.1 3 4 15 20 22 91

Special Populations

Plasma clearance may decrease substantially (>50%) in patients with severe renal impairment (i.e., Clcr ≤30 mL/minute and those requiring hemodialysis) 1 (See Renal Impairment under Dosage and Administration.)

Removed by hemodialysis.1 20

Plasma clearance decreased approximately 19–26% in geriatric patients.20




For Injection, Concentrate, for IV Infusion

25°C (may be exposed to 15–30°C).1 20 Do not freeze; protect from light.1 20

Contains no preservative; discard unused solution.1

Injection, for IV Infusion

25°C (may be exposed to 15–30°C).1 Do not freeze; protect from light.1

Contains no preservative; discard unused solution.1


For information on systemic interactions resulting from concomitant use, see Interactions.


Solution CompatibilityHID


Dextrose 5% in sodium chloride 0.45%

Dextrose 5% in water

Sodium chloride 0.9%

Drug Compatibility
Y-Site Compatibility1HID


Amiodarone HCl

Atropine sulfate


Dobutamine HCl

Dopamine HCl

Epinephrine HCl

Famotidine HCl


Heparin sodium

Lidocaine HCl

Midazolam HCl

Morphine sulfate


Potassium chloride

Propranolol HCl

Incompatible1 HID



  • Binds selectively to platelet GP IIb/IIIa receptors and reversibly inhibits platelet aggregation (by preventing binding of fibrinogen, von Willebrand factor, and other adhesive ligands to GP IIb/IIIa receptors).1 11 16 17 22 24 43 45

  • Modest effect on hemostatic indices (e.g., bleeding times);1 2 normal hemostasis restored more rapidly than with abciximab.8 31 32 35 74 91

  • Usually does not affect aPTT when administered as monotherapy.5 6

Advice to Patients

  • Risk of serious bleeding or hemorrhage.1

  • Importance of close laboratory monitoring.1

  • Importance of informing clinicians of existing or contemplated concomitant therapy, including prescription and OTC drugs and dietary or herbal supplements, as well as any concomitant illnesses (e.g., cardiovascular disease).1

  • Importance of women informing clinicians if they are or plan to become pregnant or plan to breast-feed.1

  • Importance of advising patients of other important precautionary information.1 (See Cautions.)


Excipients in commercially available drug preparations may have clinically important effects in some individuals; consult specific product labeling for details.

Please refer to the ASHP Drug Shortages Resource Center for information on shortages of one or more of these preparations.

Tirofiban Hydrochloride


Dosage Forms


Brand Names



For injection, concentrate, for IV infusion

250 mcg (of tirofiban) per mL (5 and 12.5 mg)



Tirofiban Hydrochloride in Sodium Chloride


Dosage Forms


Brand Names



Injection, for IV infusion

50 mcg (of tirofiban) per mL (5 and 12.5 mg) in 0.9% Sodium Chloride

Aggrastat Premixed in Iso-osmotic Sodium Chloride Injection (in IntraVia flexible container)


AHFS DI Essentials™. © Copyright 2020, Selected Revisions September 18, 2017. American Society of Health-System Pharmacists, Inc., 4500 East-West Highway, Suite 900, Bethesda, Maryland 20814.


1. Medicure Pharma. Aggrastat (tirofiban hydrochloride) injection premixed and injection prescribing information. Somerset, NJ; 2007 Nov.

2. Anon. Tirofiban hydrochloride. Drugs Future. 1995; 20:897-901.

3. Umemura K, Kondo K, Ikeda Y et al. Enhancement by ticlopidine of the inhibitory effect on in vitro platelet aggregation of the glycoprotein IIb/IIIa inhibitor tirofiban. Thromb Haemost. 1997; 78: 1381-4.

4. Barrett JS, Murphy G, Peerlinck K et al. Pharmacokinetics andpharmacodynamics of MK-383, a selective non-peptide platelet glycoprotein-IIb/IIIa receptor antagonist, in healthy men. Clin Pharmacol Ther. 1994; 56:377-88.

5. The Platelet Receptor Inhibition in Ischemic Syndrome Management (PRISM) Study Investigators. A comparison of aspirin plus tirofiban with aspirin plus heparin for unstable angina. N Engl J Med. 1998; 338:1498-1505.

6. The Platelet Receptor Inhibition in Ischemic Syndrome Management in Patients Limited by Unstable Signs and Symptoms (PRISM-PLUS) Study Investigators. Inhibition of the platelet glycoprotein IIb/IIIa receptor with tirofiban in unstable angina and non-Q-wave myocardial infarction. N Engl J Med. 1998; 338:1488-97.

7. Agency for Health Care Policy and Research. Diagnosing and managing unstable angina. 1994. (AHCPR publication no. 94-0603)

8. Chesebro JH, Badimon JJ. Platelet glycoprotein IIb/IIIa receptor blockade in unstable coronary disease. N Engl J Med. 1998; 338:1539-41.

9. Théroux P, Fuster V. Acute coronary syndromes: unstable angina and non-Q-wave myocardial infarction. Circulation. 1997; 97:1195-206.

10. Braunwald E, Maseri A, Armstrong PW et al. Rationale and clinical evidence for the use of GP IIb/IIIa inhibitors in acute coronary syndromes. Eur Heart J. 1998; 19(Suppl. D):D22-30.

11. The RESTORE Investigators. Effects of platelet glycoprotein IIb/IIIa blockade with tirofiban on adverse cardiac events in patients with unstable angina or acute myocardial infarction undergoing coronary angioplasty. Circulation. 1997; 96:1445-53.

12. Tcheng JE. Platelet glycoprotein IIb/IIIa integrin blockade: recent clinical trials in interventional cardiology. Thromb Haemost. 1997; 78:205-9.

13. Hahn SS, Chae C, Giugliano R et al. Troponin I levels in unstable angina/non-Q wave myocardial infarction patients treated with tirofiban, a glycoprotein IIb/IIIa antagonist. J Am Coll Cardiol. 1998; 31(Suppl. A):229A.

14. Kereiakes DJ, Kleiman NS, Ambrose J et al. Randomized, double-blind, placebo-controlled dose-ranging study of tirofiban (MK-383) platelet IIb/IIIa blockade in high risk patients undergoing coronary angioplasty. J Am Coll Cardiol. 1996; 27:536-42.

15. Peerlinck, De Lepeleire I, Goldberg M et al. MK-383 (L-700,462), a selective nonpeptide platelet glycoprotein IIb/IIIa antagonist, is active in man. Circulation. 1993; 88:1512-7.

16. Hartman GD, Egbertson MS, Halczenko W et al. Non-peptide fibrinogen receptor antagonists. 1. Discovery and design of exosite inhibitors. J Med Chem. 1992; 35:4640-2.

17. Egbertson MS, Chang CTC, Duggan ME et al. Non-peptide fibrinogen receptor antagonists. 2. Optimization of a tyrosine template as a mimic for arg-gly-asp. J Med Chem. 1994; 37:2537-51.

18. Eli Lilly and Company. ReoPro (abciximab) injection for intravenous use prescribing information. Indianapolis, IN; 1997 June. In: Physicians’ desk reference. 52nd ed. Montvale, NJ: Medical Economics Company Inc; 1998:1498-1501.

19. Bittl JA, Levin DC. Coronary arteriography. In: Braunwald E, ed. Heart disease: a textbook of cardiovascular medicine. 5th ed. Philadelphia: WB Saunders Company; 1997:240-72.

20. Merck & Co. Product information form for American hospital formulary service: Aggrastat (tirofiban hydrochloride). West Point, PA; 1998.

21. Merck & Co., West Point, PA: Personal communication.

22. Kumar A, Herrmann HC. Tirofiban: an investigational platelet glycoprotein IIb/IIIa receptor antagonist. Exp Opin Invest Drugs. 1997; 6:1257-67.

23. Randomised placebo-controlled trial of effect of eptifibatide on complication of percutaneous coronary intervention: IMPACT-II. Lancet. 1997; 349:1422-8.

24. Albeida SM, Daise M, Levine EM et al. Identification and characterization of cell-substratum adhesion receptors on cultured human endothelial cells. J Clin Invest. 1989; 83:1992-2002.

25. White H. Unmet therapeutic needs in the management of acute ischemia. Am J Cardiol. 1997; 80(suppl. 4A):2b-10b.

26. Le Breton Herve, Plow EF, Topol EJ et al. Role of platelets in restenosis after percutaneous coronary revascularization. J Am Coll Cardiol. 1996; 28:1643-51.

27. Phillips DR, Scarborough RM. Clinical pharmacology of eptifibatide. Am J Cardiol. 1997; 80(suppl. 4A):11b-20b.

28. Plow EF, Ginsberg MH. Molecular basis of platelet function. In: Hoffman R, Benz EJ, Shattil SJ et al, eds. Hematology. 2nd ed. Churchill Livingstone. New York, NY. 1995: 1524-35.

29. Moliterno DJ, Topol EJ. Conjunctive use of platelet glycoprotein IIb/IIIa antagonists and thrombolytic therapy for acute myocardial infarction. Thrombosis Haemostasis. 1997; 78: 214-9.

30. Key Pharmaceuticals. Integrelin™ (eptifibatide) injection prescribing information. Kenilworth, NJ; 1998 May.

31. Scarborough RM, Kleiman NS, Phillips DR. Platelet glycoprotein IIb/IIIa antagonists: what are the relevant issues concerning their pharmacology and clinical use? Circulation. 1999; 100:437-44.

32. Weitz JI. New antithrombotic agents. Chest. 1998; 114:715S-27S.

33. Kleiman NS, Lincoff AM, Ohman EM et al. Glycoprotein Iib/IIIa inhibitors in acute coronary syndromes: pathophysiologic foundation and clinical findings. Am Heart J. 1998; 136:S32-42.

34. Rudd MA, George D, Amarante P et al. Temporal effects of thrombolytic agents on platelet function in vivo and their modulation by prostaglandins. Circ Res. 1990; 67:1175-81.

35. Madan M, Berkowitz SD, Tcheng JE. Glycoprotein IIb/IIIa integrin blockade. Circulation. 1998; 98:2629-35.

36. Kong DF, Califf Rm, Miller DP et al. Clinical outcomes of therapeutic agents that block the platelet glycoprotein IIb/IIIa integrin in ishemic heart disease. Circulation. 1998; 98:2829-35.

37. Lincoff AM. Trials of platelet glycoprotein IIb/IIIa receptor antagonists during percutaneous coronary revascularization. Am J Cardiol. 1998; 82:36p-42p.

38. Theroux P. Tirofiban in unstable coronary disease. N Engl J Med. 1998; 339:1164.

39. White HD. Tirofiban in unstable coronary disease. N Engl J Med. 1998; 339:1164-5.

40. Chesebro JH, Badimon JJ. Tirofiban in unstable coronary disease. N Engl J Med. 1998; 339:1165.

41. Gibson CM, Goel M, Cohen DJ et al. Six-month angiographic and clinical follow-up of patients prospectively randomized to receive either tirofiban or placebo during angioplasty in the RESTORE trial. J Am Coll Cardiol. 1998; 32:28-34.

42. Adgey AAJ. An overview of the results of clinical trials with glycoprotein IIb/IIIa inhibitors. Am Heart J. 1998; 135:S43-55.

43. Quinn M, Fitzgerald DJ. Long-term administration of glycoprotein IIb/IIIa antagonists. Am Heart J. 1998; 135:S113-8.

44. Vorchheimer DA, Badimon JJ, Fuster V. Platelet glycoprotein IIb/IIIa receptor antagonists in cardiovascular disease. JAMA. 1999; 281:1407-14.

45. Topol EJ, Byzova TV, Plow EF. Platelet GPIIb/IIIa blockers. Lancet. 1999; 353:227-31.

46. Dobesh PP, Latham KA. Advancing the battle against ischemic syndromes: a focus on the GP-IIb/IIIa inhibitors. Pharmacotherapy. 1998; 18:663-85.

47. Ferguson JJ, Waly HM, Wilson JM. Fundamentals of coagulation and glycoprotein IIb/IIIa receptor inhibition. Am Heart J. 1998; 135:S35-42.

48. Zaacks SM, Liebson PR, Calvin JE et al. Unstable angina and non-Q wave myocardial infarction: does the clinical diagnosis have therapeutic implications? J Am Coll Cardiol. 1999; 33:107-18.

49. Theroux P, White H, David D et al. A heparin-controlled study of MK-383 in unstable angina. Circulation. 1994; 90(Suppl):1240.

50. Giugliano RP, Hyatt RR. Thrombocyotpenia with GP IIb/IIIa inhibitors: a meta-analysis. J Am Coll Cardiol. 1998; 31(Suppl 2A):185A.

51. Topol EJ. Targeted approaches to thrombus formation: an end to the shotgun approach. Clin Cardiol. 1997;20 (Suppl I):I-22-6.

52. Ferguson JJ, Kereiakes DJ, Adgey AAJ et al. Safe use of platelet GP IIb/IIIa inhibitors. Am Heart J. 1998; 135:S77-89.

53. Popma JJ, Weitz J, Bittl JA et al. Antithrombotic therapy in patients undergoing coronary angioplasty. Chest. 1998; 114:728s-41s.

54. Topol EJ, Ferguson JJ, Weisman HF et al. Long-term protection from myocardial ischemic events in a randomized trial of brief integrin β3 blockade with percutaneous coronary intervention. JAMA. 1997; 278:479-84.

55. EPIC Investigators. Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high-risk coronary angioplasty. N Engl J Med. 1994; 330: 956-61.

56. Tcheng JE, Harrington RA, Kottke-Marchangt K et al. Multicenter, randomized, double-blind, placebo-controlled trial of platelet integrin glycoprotein IIb/IIIa blocker Integrelin in elective coronary intervention. Circulation. 1995; 95:793-5.

57. Cairns JA, Gent M, Singer J et al. Aspirin, sulfinpyrazone, or both in unstable angina: results of a Canadian multicenter trial. N Engl J Med. 1985; 313:1369-75.

58. Théroux P, Ouimet H. McCans J et al. Aspirin, heparin, or both to treat acute unstable angina. N Engl J Med. 1988; 319:1105-11.

59. Théroux P, Waters D, Qiu S et al. Aspirin versus heparin to prevent myocardial infarction during the acute phase of unstable angina. Circulation. 1993; 88(5 Pt 1):2045-8.

60. Tonkin AM, Aroney CN. Guidelines for managing patients with unstable angina: rating the evidence and rationale for treatment. Med J Aust. 1997; 16:644-7.

61. Cohen M, Demers C, Gurfinkel EP et al. A comparison of low-molecular-weight heparin with unfractionated heparin for unstable coronary artery disease. N Engl J Med. 1997; 337: 447-52.

62. Antiplatelet Trialists’ Collaboration. Collaborative overview of randomised trials of antiplatelet therapy—I: Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. BMJ. 1994; 308:81-106.

63. Lewis HD, Davies JW, Archibald DG et al. Protective effects of aspirin against acute myocardial infarction and death in men with unstable angina. Results of a Veterans Administration Cooperative Study. N Engl J Med. 1983; 309:396-403.

64. Armstrong PW. Heparin in acute coronary disease-requiem for a heavyweight? N Engl J Med. 1997; 337:492-494. (IDIS 389821)

65. Swahn E, Wallentin L for the FRISC study group. Low-molecular weight heparin (fragmin) during instability in coronary artery disease (FRISC). Am J Cardiol. 1997; 80(Suppl. 5A):25E-9E.

66. Fragmin during Instability in Coronary Artery Disease (FRISC) study group. Low-molecular-weight heparin during instability in coronary artery disease. Lancet. 1996; 347:561-8.

67. Cairns J, Théroux P, Armstrong P et al. Unstable angina—Report from a Canadian expert round table. Can J Cardiol. 1996; 12:1279-92.

68. Théroux P. Antiplatelet therapy: do the new platelet inhibitors add significantly to the clinical benefits of aspirin? Am Heart J. 1997; 134:S62-70.

69. Oler A, Whooley MA, Oler J et al. Adding heparin to aspirin reduces the incidence of myocardial infarction and death in patients with unstable angina: a meta-analysis. JAMA. 1996; 276:811-5.

70. Simko RJ, Tsung FFW, Stamek EJ et al. Activated clotting time versus activated partial thromboplastin time for therapeutic monitoring of heparin. Ann Pharmacother. 1995; 29:1015-21.

71. Lefkovits J, Plow EF, Topol EJ. Platelet glycoprotein IIb/IIIa receptors in cardiovascular medicine. N Engl J Med. 1995; 332:1553-9.

72. Alexander JH, Harrington RA. Recent antiplatelet drug trials in the acute coronary syndromes. Clinical interpretation of PRISM, PRISM-PLUS, PARAGON A, and PURSUIT. Drugs. 1998; 56:965-76.

73. Goa KL, Noble S. Eptifibatide. A review of its use in patients with acute coronary syndromes and/or undergoing percutaneous coronary intervention. Drugs. 1999; 57:439-62.

74. Kleiman NS. A risk-benefit assessment of abciximab in angioplasty. Drug Saf. 1999; 20:43-57.

75. Detre KM, Holmes DR Jr, Holubkov R et al. Incidence and consequences of periprocedural occlusion: the 1985–1986 National Heart, Lung, and Blood Institute Percutaneous Transluminal Coronary Angioplasty Registry. Circulation. 1990; 82:739-50.

76. The RISC Group. Risk of myocardial infarction and death during treatment with low dose aspirin and intravenous heparin in men with unstable coronary artery disease. Lancet. 1990; 336:827-30.

77. Reviewers’ comments (personal observations) on eptifibatide.

78. Catella-Lawson F, FitzGerald GA. Trials in myocardial infarction. Circulation. 1997; 96:3815.

79. Catella-Lawson F, Fitzgerald GA. Confusion in reperfusion: problems in the clinical development of antithrombotic drugs. Circulation. 1997; 95: 793-5.

80. Tcheng JE. Glycoprotein IIb/IIIa receptor inhibitors: putting the EPIC, IMPACT II, RESTORE, and EPILOG trials into perspective. Am J Cardiol. 1996; 78(Suppl 3A):35-40.

81. Cor Therapeutics, South San Francisco, CA, and Key Pharmaceuticals, Kenilworth, NJ: Personal communication on eptifibatide.

82. Cohen M, Adams PC, Gareth P et al. Combination antithrombotic therapy in unstable rest angina and non-Q-wave infarction in nonprior aspirin users: Primary end points analysis for the ATACS trial. Circulation. 1994; 89:81-8.

83. Cairns JA, Theroux P, Lewis HD Jr et al. Antithrombotic agents in coronary artery disease. Chest. 1998; 114(Suppl): 611-33S.

84. Patrono C, Coller B, Dalen JE et al. Platelet-active drugs. The relationship among dose, effectiveness, and side effects. Chest. 1998; 114(Suppl): 470-88S.

85. PURSUIT Trial Investigators. Inhibition of platelet glycoprotein IIb/IIIa with eptifibatide in patients with acute coronary syndromes. N Engl J Med. 1998; 339:436-43.

86. Granger CB, Miller JM, Bovill EG et al. Rebound increase in thrombin generation and activity after cessation of intravenous heparin in patients with acute coronary syndromes. Circulation. 1995; 91:1929-35.

87. Kereiakes DJ, Broderick TM, Roth EM et al. Time course, magnitude, and consistency of platelet inhibition by abciximab, tirofiban, or eptifibatide in patients with unstable angina pectoris undergoing percutaneous coronary intervention. Am J Cardiol. 1999; 84:391-5.

88. Rao AK, Pratt C, Berke A et al. Thrombolysis in myocardial infarction (TIMI) trial-phase I: hemorrhagic manifestations and changes in plasma fibrinogen and fibrinolytic system in patients treated with recombinant tissue plasminogen activator and streptokinase. J Am Coll Cardiol. 1988; 11:1-11.

89. Ryan TJ, Antman EM, Brooks NH et al. 1999 update: ACC/AHA guidelines for the management of patients with acute myocardial infarction: executive summary and recommendations: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on Management of Acute Myocardial Infarction). Circulation. 1999;100:1016-30.

90. Moll S. Eptifibatide in acute coronary syndromes. N Engl J Med. 1999; 340:60-1.

91. Reviewers’ comments (personal observations).

92. Phillips DB, Teng W, Arfsten A et al. Effect ofCa2 on GP IIb/IIIa interactions with Integrelin: enhanced GP IIb/IIIa binding and inhibition of platelet aggregation by reductions in the concentration of ionized calcium in plasma coagulated with citrate. Circulation. 1997; 96:1488-94.

93. Ellis SG, Tcheng JE, Navetta TI et al. Safety and antiplatelet effect of murine monoclonal antibody FE3 Fab directed against platelet glycoprotein IIb/IIIa in patients undergoing elective coronary angioplasty. Coron Artery Dis. 1993; 4:167-75.

94. Calvin JE, Klein LW, Vandenberg BJ et al. Risk stratification in unstable angina: prospective validation of Braunwald classification. JAMA. 1995; 273:136-41.

95. The EPILOG investigators. Platelet glycoprotein IIb/IIIa receptor blockade and low-dose heparin during percutaneous coronary revascularization. 1997; 336:1689-96.

96. Antman EM, Grudzien C, Mitchell RN et al. Detection of unsuspected myocardial necrosis by rapid bedside assay for cardiac troponin T. Am Heart J. 1997; 133:596-8.

97. Armstrong PW. Pursuing progress in acute coronary syndromes. Circulation. 1999; 100:1586-9.

98. Antman EM, Fox KM for the International Cardiology Forum. Guidelines for the diagnosis and management of unstable angina and non-Q-wave myocardial infarction: proposed revisions. Am Heart J. 2000; 139:461-75.

99. Kaul S, Shah PK. Low molecular weight heparin in acute coronary syndrome: evidence for superior or equivalent efficacy compared with unfractionated heparin? J Am Coll Cardiol. 2000; 35:1699-702.

108. Topol EJ, Moliterno DJ, Hermann HC et al. Comparison of two platelet glycoprotein IIb/IIIa inhibitors, tirofiban and abciximab, for the prevention of ischemic events with percutaneous coronary revascularization. N Engl J Med. 2001; 344:1888-94.

109. Lansky AJ, Hochman JS, Ward PA et al. Percutaneous coronary intervention and adjunctive pharmacotherapy in women: a statement for healthcare professional from the American Heart Association. Circulation. 2005; 111:940-3.

991. Anderson JL, Adams CD, Antman EM et al. 2011 ACCF/AHA Focused Update Incorporated Into the ACC/AHA 2007 Guidelines for the Management of Patients With Unstable Angina/Non-ST-Elevation Myocardial Infarction: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation. 2011; 123:e426-579.

994. Levine GN, Bates ER, Blankenship JC et al. 2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention. A report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Society for Cardiovascular Angiography and Interventions. J Am Coll Cardiol. 2011; 58:e44-122.

995. Hamm CW, Bassand JP, Agewall S et al, for The Task Force for the management of acute coronary syndromes (ACS) in patients presenting without persistent ST -segment elevation of the European Society of Cardiology (ESC). ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. Eur Heart J. 2011; 32:2999-3054.

1016. Eikelboom JW, Hirsh J, Spencer FA et al. Antiplatelet drugs: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 2012; 141(2 Suppl):e89S-119S.

1100. Amsterdam EA, Wenger NK, Brindis RG et al. 2014 AHA/ACC guideline for the management of patients with non-ST-elevation acute coronary syndromes: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation. 2014; 130:e344-426.

b. AHFS drug information 2018. McEvoy GK, ed. Tirofiban. Bethesda, MD: American Society of Health-System Pharmacists; 2018.

HID. Trissel LA. Handbook on injectable drugs. 13th ed. Bethesda, MD: American Society of Health-System Pharmacists; 2005:1415-1417.